Skip to main content

. 1987 Oct;24(4):559–560. doi: 10.1111/j.1365-2125.1987.tb03213.x

Effect of oral administration of a new calcium channel blocking agent, bepridil on antipyrine clearance in man.

C Funck-Brentano ¹, P L Chaffin ¹, G R Wilkinson ¹, B McAllister ¹, R L Woosley ¹

PMCID: PMC1386322 PMID: 3500736

559

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Antonini E., Brunori M., Colosimo A., Sarti P. Effect of bepridil on the activity of cytochrome c oxidase in solution and in proteoliposomes. Biochem Pharmacol. 1984 Jan 1;33(1):109–113. doi: 10.1016/0006-2952(84)90377-0. [DOI] [PubMed] [Google Scholar]
Bauer L. A., Stenwall M., Horn J. R., Davis R., Opheim K., Greene L. Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy. Clin Pharmacol Ther. 1986 Aug;40(2):239–242. doi: 10.1038/clpt.1986.169. [DOI] [PubMed] [Google Scholar]
Rumiantsev D. O., Piotrovskii V. K., Riabokon O. S., Slastnikova I. D., Kokurina E. V., Metelitsa V. I. The effect of oral verapamil therapy on antipyrine clearance. Br J Clin Pharmacol. 1986 Nov;22(5):606–609. doi: 10.1111/j.1365-2125.1986.tb02942.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
Teunissen M. W., Meerburg-van der Torren J. E., Vermeulen N. P., Breimer D. D. Automated high-performance liquid chromatographic determination of antipyrine and its main metabolites in plasma, saliva and urine, including 4,4'-dihydroxyantipyrine. J Chromatogr. 1983 Dec 9;278(2):367–378. [PubMed] [Google Scholar]
Vesell E. S. The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clin Pharmacol Ther. 1979 Sep;26(3):275–286. doi: 10.1002/cpt1979263275. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES